We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+1.82%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$23.1M
Cap. Flow
+$26.6M
Cap. Flow %
20.15%
Top 10 Hldgs %
76.57%
Holding
38
New
12
Increased
12
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
OKUR
OnKure Therapeutics
OKUR
+$8.19M
2
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$3.38M
3
CNTB
Connect Biopharma Holdings
CNTB
+$2.45M
4
DSGN icon
Design Therapeutics
DSGN
+$2.36M
5
AVIR icon
Atea Pharmaceuticals
AVIR
+$2.01M

Top Sells

Rank Stock Value
1
PASG icon
Passage Bio
PASG
+$1.35M
2
RVP icon
Retractable Technologies
RVP
+$595K
3
LONA
LeonaBio Inc
LONA
+$443K
4
SRZN icon
Surrozen
SRZN
+$43.7K

Sector Composition

Rank Sector Weight
1 Healthcare 60.16%
2 Technology 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGOV icon
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$97.5B
$27.1M 20.51%
270,000
– –
BIL icon
2
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
$18.3M 13.84%
200,000
– –
AVIR icon
3
Atea Pharmaceuticals
AVIR
$390M
$16.7M 12.62%
5,462,079
+662,079
+14% +$2.01M
CYT
4
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$9.88M 7.48%
3,250,008
– –
TRML
5
DELISTED
Tourmaline Bio
TRML
$6.43M 4.87%
245,500
+45,500
+23% +$911K
CLYM
6
Climb Bio
CLYM
$727M
$5.89M 4.46%
2,180,000
+241,737
+12% +$629K
TECX
7
Tectonic Therapeutic
TECX
$615M
$5.44M 4.12%
333,469
– –
THRX
8
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$4.49M 3.4%
+1,108,320
New +$3.38M
LONA
9
LeonaBio Inc
LONA
$67.8M
$3.53M 2.68%
145,436
-25,000
-15% -$443K
ADVM
10
DELISTED
Adverum Biotechnologies
ADVM
$3.43M 2.6%
455,425
+63,925
+16% +$584K
ANF icon
11
PUT
Abercrombie & Fitch
ANF
$4.23B
$3.03M 2.3%
+900
New +$64K
ORMP icon
12
Oramed Pharmaceuticals
ORMP
$165M
$2.91M 2.21%
1,261,559
+480,267
+61% +$1.03M
DSGN icon
13
Design Therapeutics
DSGN
$785M
$2.73M 2.07%
+1,029,478
New +$2.36M
CNTB
14
Connect Biopharma Holdings
CNTB
$150M
$2.43M 1.84%
+2,061,438
New +$2.45M
OKUR
15
OnKure Therapeutics
OKUR
$170M
$2.1M 1.59%
+131,423
New +$8.19M
ASTC icon
16
Astrotech Corp
ASTC
$15.5M
$1.87M 1.42%
220,410
– –
RAIN
17
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$1.62M 1.23%
1,349,007
+1,276,081
+1,750% +$1.38M
FBRX icon
18
Forte Biosciences
FBRX
$1B
$1.45M 1.1%
70,468
– –
VRCA icon
19
Verrica Pharmaceuticals
VRCA
$96M
$1.32M 1%
18,000
+3,000
+20% +$123K
WING icon
20
PUT
Wingstop
WING
$3.88B
$1.21M 0.92%
+900
New +$194K
ORKA
21
Oruka Therapeutics
ORKA
$5.59B
$1.2M 0.91%
58,911
– –
LENZ
22
LENZ Therapeutics
LENZ
$162M
$1.17M 0.89%
+63,917
New +$1.06M
KNTE
23
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.11M 0.84%
+468,210
New +$829K
VTGN icon
24
VistaGen Therapeutics
VTGN
$9.4M
$771K 0.58%
150,000
+50,000
+50% +$189K
MIST icon
25
Milestone Pharmaceuticals
MIST
$148M
$739K 0.56%
442,352
+169,852
+62% +$461K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, BML Capital Management held 38 positions worth $132M, up 21% from $109M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

BML Capital Management deployed $26.6M of net new capital in Q4 2023, opening 12 new positions and adding to 12 existing holdings. Its largest new stake was OnKure Therapeutics: 131,423 shares worth $2.1M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was LeonaBio Inc, an estimated $443K trimmed.

  • BML Capital Management's largest Q4 2023 buy was OnKure Therapeutics: 131,423 shares worth $2.1M.
  • BML Capital Management added most to Atea Pharmaceuticals in Q4 2023, an estimated $2.01M increase.
  • BML Capital Management's biggest Q4 2023 reduction was LeonaBio Inc, cutting an estimated $443K.
  • BML Capital Management fully exited Passage Bio in Q4 2023, selling an estimated $1.35M.
  • BML Capital Management's ten largest holdings make up 77% of its $132M portfolio in Q4 2023.
  • BML Capital Management opened 12 new positions and closed 3 in Q4 2023.
  • BML Capital Management's portfolio value rose 21% quarter-over-quarter to $132M.

Based on BML Capital Management's 13F filing for Q4 2023, filed 30 Jan 2024.